|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, the mechanism by which miR-145 contributes to regulate PD-L1 expression in cisplatin-resistance of ovarian cancer is yet to be fully understood.
|
31821542 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis based on tumor type showed that the downregulation of miR-145 was associated with unfavorable OS in colorectal cancer (HR = 2.17; 95% CI, 1.52-3.08; <i>P</i> < 0.001), ovarian cancer (HR = 2.15; 95% CI, 1.29-3.59; <i>P</i> = 0.003), gastric cancer (HR = 1.78; 95% CI, 1.35-2.36; <i>P</i> < 0.001), glioma (HR = 1.65; 95% CI, 1.30-2.10; <i>P</i> < 0.001), and osteosarcoma (HR = 2.28; 95% CI, 1.50-3.47; <i>P</i> < 0.001).
|
30602498 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, decreased expression of hsa‑miR‑145 in OC and OC‑derived exosomes may be a crucial biomarker for the diagnosis and treatment of OC.
|
30365097 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
CTD_human |
Downregulation of miR-145-5p in cancer cells and their derived exosomes may contribute to the development of ovarian cancer by targeting CT.
|
30365097 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, miR‑145 was suggested to be a potential miRNA‑based therapeutic target in ovarian cancer.
|
30864742 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum exosomal miR-145 in particular appeared to be the most promising biomarker for preoperative diagnosis of ovarian cancer.
|
31205555 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, a feedback loop between miR-145 and DNMT3A is a potent signature for the Warburg effect in ovarian cancer, promising a potential target for improved anticancer treatment.
|
29993160 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanisms of miR-145 regulating invasion and metastasis of ovarian carcinoma.
|
28804560 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results from nude mouse xenograft models further demonstrate the suppressive effect of miR-145 on malignant progression of ovarian cancer.
|
28881818 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
miR-145 expression was downregulated in EOC tissues and cell lines as compared with normal ovarian tissues.
|
26472353 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low miR-145 and high HMGA2 expressions are potential biomarkers of poor prognosis of ovarian carcinoma and miR-145 is the more powerful predictor of patient outcome.
|
25444913 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the result indicated that miR- 145 could be used as a potential therapeutic target in ovarian cancer.
|
23919393 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the present study, Northern blot and qRT-PCR analysis indicate that miR-145 is downregulated in ovarian cancer tissues and cell lines, as well as in serum samples of ovarian cancer, compared to healthy ovarian tissues, cell lines and serum samples.
|
24157791 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The loss of miR-145 can result in the activation of factors that promote oncogenesis and cellular pluripotency which in turn could lead to the development of ovarian cancer.
|
22285623 |
2012 |